Elsnerova Katerina, Bartakova Alena, Tihlarik Josef, Bouda Jiri, Rob Lukas, Skapa Petr, Hruda Martin, Gut Ivan, Mohelnikova-Duchonova Beatrice, Soucek Pavel, Vaclavikova Radka
Toxicogenomics Unit, National Institute of Public Health, Srobarova 48, 100 42 Prague 10, Czech Republic.
Third Faculty of Medicine, Charles University, Ruska 87, 100 00 Prague 10, Czech Republic.
J Cancer. 2017 Oct 9;8(17):3598-3606. doi: 10.7150/jca.20766. eCollection 2017.
Epithelial ovarian cancer (EOC) has the highest mortality among gynecological carcinomas. The lack of specific markers for prognostic determination of EOC progression hinders the search for novel effective therapies. The aim of the present study was (i) to explore differences in expressions of ATP-binding cassette (ABC) and solute carrier (SLC) transporter genes, genes associated with drug metabolism and cell cycle regulation between control ovarian tissues (n = 14), primary EOCs (n = 44) and intraperitoneal metastases (n = 29); (ii) to investigate associations of gene expression levels with prognosis of patients with intraperitoneal metastases. In all tissue samples, transcript levels of the above target genes were assessed using quantitative real-time PCR. Gene expression levels were compared between particular tissue types and evaluated with regard to progression-free survival (PFS) and drug-resistance status of patients with metastases. Gene expression of significantly increased and that of decreased in the order control ovarian tissues - primary EOCs - metastases. High expressions of ///, , , , , , and genes were significantly associated with longer progression-free survival of patients. In intraperitoneal metastases, expression of all of these genes highly correlated and indicated prognostic profile. Transporters from the ABCA family, ABCG2, and ESR2 are involved mainly in lipid metabolism, membrane transport, and cell proliferation. These processes are thus probably the most important for EOC progression. Based on these results, we have proposed novel markers of ovarian carcinoma progression and metastatic spread which might be potentially useful as therapeutic targets. Their significance should be further explored on a larger independent set of patients.
上皮性卵巢癌(EOC)在妇科癌症中死亡率最高。缺乏用于EOC进展预后判定的特异性标志物阻碍了新型有效疗法的探索。本研究的目的是:(i)探究对照卵巢组织(n = 14)、原发性EOC(n = 44)和腹腔转移灶(n = 29)中ATP结合盒(ABC)和溶质载体(SLC)转运蛋白基因、与药物代谢及细胞周期调控相关基因表达的差异;(ii)研究基因表达水平与腹腔转移患者预后的相关性。在所有组织样本中,使用定量实时PCR评估上述靶基因的转录水平。比较特定组织类型之间的基因表达水平,并根据转移患者的无进展生存期(PFS)和耐药状态进行评估。基因表达在对照卵巢组织-原发性EOC-转移灶中呈依次显著升高和降低的趋势。///、、、、、和基因的高表达与患者更长的无进展生存期显著相关。在腹腔转移灶中,所有这些基因的表达高度相关并提示预后特征。ABCA家族转运蛋白、ABCG2和ESR2主要参与脂质代谢、膜转运和细胞增殖。因此,这些过程可能对EOC进展最为重要。基于这些结果,我们提出了卵巢癌进展和转移扩散的新型标志物,它们可能作为潜在的治疗靶点。其意义应在更大的独立患者队列中进一步探索。